Simonsz-Tóth Brigitte, Joosse Maurits V, Besch Dorothea
Department of Ophthalmology, Haaglanden Medical Centre, The Hague, The Netherlands.
Department of Ophthalmology, Eberhard Karls University, Tübingen, Germany.
Graefes Arch Clin Exp Ophthalmol. 2019 Feb;257(2):379-389. doi: 10.1007/s00417-018-4170-y. Epub 2018 Nov 5.
Since neurophysiological and clinical trials have shown evidence for plasticity in the adult visual system, the upper age limit for amblyopia treatment is not rigid. The aim of this study was to investigate the efficacy of occlusion therapy and refractive adaptation in untreated amblyopic patients 12 to 40 years of age.
In a prospective study, all patients had full orthoptic and ophthalmic assessment including cycloplegic retinoscopy. Patients with a newly prescribed optical correction underwent an 18-week refractive adaptation. All patients were treated with occlusion for 3 h a day for 18 weeks. Acuity gain and responder rates (≥ 0.2 log units) were calculated. The rate of recurrence (visual acuity 9 months after end of the occlusion therapy; ≥ 0.2 log units) and the acuity gain after refractive adaptation were determined. Self-reported compliance to occlusion therapy was assessed.
Median age of patients (n = 24) was 32.4 years (IQR 19.2). Best corrected visual acuity at start of occlusion therapy was 0.35 logMAR (IQR 0.5) and 0.30 (IQR 0.4) logMAR at the end of occlusion therapy, an acuity gain of 0.05 logMAR (P = 0.004). Six (25%) patients had an acuity gain of at least 0.2 logMAR units. Reading acuity was improved from 0.4 logMAR (IQR 0.4) to 0.3 logMAR (IQR 0.4) (P = 0.004). Visual acuity was stable 9 months after occlusion therapy. The acuity gain after 18 weeks of refractive adaptation was 0.05 logMAR (P = 0.238, n = 8). Acuity gain by correcting refractive errors was 0.25 logMAR (P = 0.006). Twenty-one (92%) of 24 patients achieved full recording in the calendar. Overall compliance was 17% (IQR 38). Only 5 out of 22 (23%) had acceptable compliance (≥ 50%) to occlusion therapy. Improvement of visual acuity was significantly better in patients with at least 50% compliance (P = 0.013). Compliance was worse in non-native patients than in native patients (P = 0.022).
In adulthood, compliance to occlusion therapy is even more challenging than in children. Noncompliance is the main reason for treatment failure. Only a few patients with acceptable compliance to occlusion therapy had a small but significant improvement of visual acuity. The results suggest that some adults with amblyopia retain a degree of cortical plasticity. We found that untreated adult amblyopic patients did not wear optical correction on the amblyopic eye. The highest treatment benefit was achieved by correcting refractive errors prior to following period of refractive adaptation.
由于神经生理学和临床试验已证明成人视觉系统具有可塑性,弱视治疗的年龄上限并非严格固定。本研究的目的是调查遮盖疗法和屈光适应疗法对12至40岁未经治疗的弱视患者的疗效。
在一项前瞻性研究中,所有患者均接受了全面的视光学和眼科评估,包括睫状肌麻痹验光。新配矫正眼镜的患者进行了为期18周的屈光适应。所有患者每天遮盖3小时,持续18周。计算视力提高幅度和有效反应率(≥0.2对数单位)。确定复发率(遮盖疗法结束后9个月的视力;≥0.2对数单位)以及屈光适应后的视力提高幅度。评估患者自我报告的遮盖疗法依从性。
患者(n = 24)的中位年龄为32.4岁(四分位间距19.2)。遮盖疗法开始时的最佳矫正视力为0.35 logMAR(四分位间距0.5),遮盖疗法结束时为0.30(四分位间距0.4)logMAR,视力提高了0.05 logMAR(P = 0.004)。6名(25%)患者的视力提高至少0.2 logMAR单位。阅读视力从0.4 logMAR(四分位间距0.4)提高到0.3 logMAR(四分位间距0.4)(P = 0.004)。遮盖疗法结束9个月后视力稳定。屈光适应18周后的视力提高幅度为0.05 logMAR(P = 0.238,n = 8)。通过矫正屈光不正获得的视力提高幅度为0.25 logMAR(P = 0.006)。24名患者中有21名(92%)在日历上完成了完整记录。总体依从性为17%(四分位间距38)。22名患者中只有5名(23%)对遮盖疗法的依从性可接受(≥50%)。依从性至少为50%的患者视力改善明显更好(P = 0.013)。非本地患者的依从性比本地患者差(P = 0.022)。
在成年期,遮盖疗法的依从性比儿童期更具挑战性。不依从是治疗失败的主要原因。只有少数对遮盖疗法依从性可接受的患者视力有小幅但显著的改善。结果表明,一些成年弱视患者仍保留一定程度的皮质可塑性。我们发现未经治疗的成年弱视患者弱视眼未佩戴矫正眼镜。在屈光适应期之前矫正屈光不正可获得最高的治疗效益。